vs
Empire State Realty OP, L.P.（ESBA）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Empire State Realty OP, L.P.的1.0倍（$207.3M vs $199.2M），Empire State Realty OP, L.P.净利率更高（16.1% vs -62.0%，领先78.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 0.8%），Empire State Realty OP, L.P.自由现金流更多（$50.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 4.9%）
Empire State Realty OP, L.P. 是一家房地产运营合伙企业，核心业务为持有、管理及出租优质商业与零售物业，主要布局纽约大都会区，旗下拥有帝国大厦等标志性地标，服务企业租户、零售品牌及旅游相关业务板块。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ESBA vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.2M | $207.3M |
| 净利润 | $32.2M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 17.8% | -54.7% |
| 净利率 | 16.1% | -62.0% |
| 营收同比 | 0.8% | 25.9% |
| 净利润同比 | 71.2% | 3.5% |
| 每股收益（稀释后） | $0.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.2M | $207.3M | ||
| Q3 25 | $197.7M | $159.9M | ||
| Q2 25 | $191.3M | $166.5M | ||
| Q1 25 | $180.1M | $139.3M | ||
| Q4 24 | $197.6M | $164.6M | ||
| Q3 24 | $199.6M | $139.5M | ||
| Q2 24 | $189.5M | $147.0M | ||
| Q1 24 | $181.2M | $108.8M |
| Q4 25 | $32.2M | $-128.6M | ||
| Q3 25 | $13.6M | $-180.4M | ||
| Q2 25 | $11.4M | $-115.0M | ||
| Q1 25 | $15.8M | $-151.1M | ||
| Q4 24 | $18.8M | $-133.2M | ||
| Q3 24 | $22.8M | $-133.5M | ||
| Q2 24 | $28.6M | $-131.6M | ||
| Q1 24 | $10.2M | $-170.7M |
| Q4 25 | 17.8% | -54.7% | ||
| Q3 25 | 19.9% | -106.9% | ||
| Q2 25 | 18.4% | -64.8% | ||
| Q1 25 | 14.3% | -102.6% | ||
| Q4 24 | 21.7% | -74.3% | ||
| Q3 24 | 22.7% | -94.6% | ||
| Q2 24 | 20.8% | -79.1% | ||
| Q1 24 | 17.1% | -151.9% |
| Q4 25 | 16.1% | -62.0% | ||
| Q3 25 | 6.9% | -112.8% | ||
| Q2 25 | 6.0% | -69.0% | ||
| Q1 25 | 8.8% | -108.5% | ||
| Q4 24 | 9.5% | -80.9% | ||
| Q3 24 | 11.4% | -95.7% | ||
| Q2 24 | 15.1% | -89.5% | ||
| Q1 24 | 5.6% | -156.8% |
| Q4 25 | $0.11 | $-1.28 | ||
| Q3 25 | $0.05 | $-1.81 | ||
| Q2 25 | $0.04 | $-1.17 | ||
| Q1 25 | $0.05 | $-1.57 | ||
| Q4 24 | $0.07 | $-1.34 | ||
| Q3 24 | $0.08 | $-1.40 | ||
| Q2 24 | $0.10 | $-1.52 | ||
| Q1 24 | $0.03 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $132.7M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $-80.0M |
| 总资产 | $4.5B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $132.7M | $421.0M | ||
| Q3 25 | $154.1M | $202.5M | ||
| Q2 25 | $94.6M | $176.3M | ||
| Q1 25 | $187.8M | $127.1M | ||
| Q4 24 | $385.5M | $174.0M | ||
| Q3 24 | $421.9M | $150.6M | ||
| Q2 24 | $535.5M | $480.7M | ||
| Q1 24 | $333.6M | $112.3M |
| Q4 25 | — | $-80.0M | ||
| Q3 25 | — | $9.2M | ||
| Q2 25 | — | $151.3M | ||
| Q1 25 | — | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | — | $346.8M | ||
| Q2 24 | — | $432.4M | ||
| Q1 24 | — | $140.3M |
| Q4 25 | $4.5B | $1.5B | ||
| Q3 25 | $4.1B | $1.2B | ||
| Q2 25 | $4.1B | $1.3B | ||
| Q1 25 | $4.1B | $1.3B | ||
| Q4 24 | $4.5B | $1.5B | ||
| Q3 24 | $4.4B | $1.5B | ||
| Q2 24 | $4.4B | $1.6B | ||
| Q1 24 | $4.2B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $249.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $50.6M | $-100.8M |
| 自由现金流率自由现金流/营收 | 25.4% | -48.6% |
| 资本支出强度资本支出/营收 | 99.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 7.74× | — |
| 过去12个月自由现金流最近4个季度 | $109.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $249.1M | $-99.8M | ||
| Q3 25 | $105.3M | $-91.4M | ||
| Q2 25 | $26.7M | $-108.3M | ||
| Q1 25 | $83.1M | $-166.5M | ||
| Q4 24 | $260.9M | $-79.3M | ||
| Q3 24 | $102.8M | $-67.0M | ||
| Q2 24 | $37.1M | $-77.0M | ||
| Q1 24 | $70.9M | $-190.7M |
| Q4 25 | $50.6M | $-100.8M | ||
| Q3 25 | $72.8M | $-92.7M | ||
| Q2 25 | $-55.1M | $-110.7M | ||
| Q1 25 | $41.1M | $-167.8M | ||
| Q4 24 | $88.0M | $-79.5M | ||
| Q3 24 | $-65.1M | $-68.6M | ||
| Q2 24 | $19.5M | $-79.0M | ||
| Q1 24 | $23.2M | $-193.9M |
| Q4 25 | 25.4% | -48.6% | ||
| Q3 25 | 36.8% | -58.0% | ||
| Q2 25 | -28.8% | -66.5% | ||
| Q1 25 | 22.8% | -120.5% | ||
| Q4 24 | 44.5% | -48.3% | ||
| Q3 24 | -32.6% | -49.2% | ||
| Q2 24 | 10.3% | -53.7% | ||
| Q1 24 | 12.8% | -178.2% |
| Q4 25 | 99.6% | 0.5% | ||
| Q3 25 | 16.5% | 0.8% | ||
| Q2 25 | 42.8% | 1.5% | ||
| Q1 25 | 23.4% | 1.0% | ||
| Q4 24 | 87.5% | 0.1% | ||
| Q3 24 | 84.1% | 1.2% | ||
| Q2 24 | 9.3% | 1.4% | ||
| Q1 24 | 26.3% | 3.0% |
| Q4 25 | 7.74× | — | ||
| Q3 25 | 7.72× | — | ||
| Q2 25 | 2.35× | — | ||
| Q1 25 | 5.27× | — | ||
| Q4 24 | 13.88× | — | ||
| Q3 24 | 4.51× | — | ||
| Q2 24 | 1.30× | — | ||
| Q1 24 | 6.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESBA
| Real Estate Segment | $163.8M | 82% |
| Observatory Segment | $35.2M | 18% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
